| ACM | Arrhythmogenic cardiomyopathy |
| ADAM | A Disintegrin and Metalloproteinase |
| ADAMTS | Disintegrin and Metalloproteinase with Thrombospondin Motifs |
| AF | Atrial fibrillation |
| AI | Artificial intelligence |
| α-SMA | Alpha-smooth muscle actin |
| ASCOT | Anglo-Scandinavian Cardiac Outcomes Trial |
| BNP | B-type natriuretic peptide |
| CAD | Coronary artery disease |
| CD44 | Cluster of differentiation 44 |
| CHD | Coronary heart disease |
| CITP | Carboxy-terminal telopeptide of type I collagen |
| CKD | Chronic kidney disease |
| CMR | Cardiac magnetic resonance |
| CVF | Collagen volume fraction |
| DAMPs | Damage-associated molecular patterns |
| DCM | Dilated cardiomyopathy |
| DE-CMR | Delayed-enhancement cardiac magnetic resonance |
| DECAAF | Delayed-Enhancement MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation |
| ECM | Extracellular matrix |
| ECV | Extracellular volume |
| E/e′ | Ratio of early mitral inflow velocity to early diastolic mitral annular velocity |
| eGFR | Estimated glomerular filtration rate |
| ELISA | Enzyme-linked immunosorbent assay |
| EMPEROR | Empagliflozin Outcome Trial in Patients with Chronic Heart Failure |
| EndMT | Endothelial-to-mesenchymal transition |
| ERK1/2 | Extracellular signal-regulated kinase 1/2 |
| FDA | Food and Drug Administration |
| Gal-3 | Galectin-3 |
| HCM | Hypertrophic cardiomyopathy |
| HF | Heart failure |
| HFmrEF | Heart failure with mildly reduced ejection fraction |
| HFpEF | Heart failure with preserved ejection fraction |
| HFrEF | Heart failure with reduced ejection fraction |
| HIV | Human immunodeficiency virus |
| HOMAGE | Heart Omics in AGEing |
| IL-33 | Interleukin-33 |
| JNK1/2 | c-Jun N-terminal kinase 1/2 |
| LA | Left atrial |
| LGE | Late gadolinium enhancement |
| LV | Left ventricular |
| MAPK | Mitogen-activated protein kinase |
| MF | Myocardial fibrosis |
| MI | Myocardial infarction |
| MMP | Matrix metalloproteinase |
| MMP-1 | Matrix metalloproteinase-1 |
| MMP-9 | Matrix metalloproteinase-9 |
| MMP-12 | Matrix metalloproteinase-12 |
| MVP | Mitral valve prolapse |
| NT-proBNP | N-terminal pro-B-type natriuretic peptide |
| PAH | Pulmonary arterial hypertension |
| MeSH | Medical Subject Headings |
| PICP | C-terminal propeptide of procollagen type I |
| PI3K/Akt | Phosphoinositide 3-kinase/Protein kinase B signaling pathway |
| PINP | N-terminal propeptide of procollagen type I |
| PIIINP | N-terminal propeptide of procollagen type III |
| PIP | Procollagen type I C-terminal propeptide |
| RAAS | Renin–angiotensin–aldosterone system |
| RCT | Randomized controlled trial |
| ROCKs | Rho-associated coiled-coil-containing protein kinases |
| ROS | Reactive oxygen species |
| SGLT2 | Sodium–glucose cotransporter 2 |
| SIV | Simian immunodeficiency virus |
| SMAD | Intracellular signaling proteins mediating TGF-β signaling |
| sST2 | Soluble suppression of tumorigenicity 2 |
| SPP1 | Secreted phosphoprotein 1 |
| TAC | Transverse aortic constriction |
| TGF-β | Transforming growth factor beta |
| TIMP | Tissue inhibitor of metalloproteinases |
| TIMP-1 | Tissue inhibitor of metalloproteinases 1 |
| TIMP-3 | Tissue inhibitor of metalloproteinases 3 |
| TIMP-4 | Tissue inhibitor of metalloproteinases 4 |
| VEGF | Vascular endothelial growth factor |